Modulation of liver injury by interleukin-10

Acta Gastro-Enterologica Belgica

Volumn 66, Issue 1, 2003, Pages 7-14

  Louis, H ^a,b   Le Moine, O ^a   Goldman, M ^a   Deviere J ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Cytokines; Hepatitis; Inflammation; Interleukin 10; Liver; Liver injury; Mice; Tumor necrosis factor alpha

Indexed keywords

CONCANAVALIN A; CYTOKINE; GALACTOSAMINE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLOGRAFT; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; ENDOTHELIUM CELL; GRAFT REJECTION; HEPATITIS; IMMUNE RESPONSE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN;

ANIMALS; CYTOKINES; HUMANS; INTERLEUKIN-10; LIVER; LIVER DISEASES;

EID: 0037222997     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (112)

1. CREAVEN P.J., BRENNER D.E., COWENS J.W. et al. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother. Pharmacol., 1989, 23: 186-191.
2. ANDO K., MORIYAMA T., GUIDOTTI L.G. et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J. Exp. Med., 1993, 178: 1541-1554.
3. TOYONAGA T., HINO O., SUGAI S. et al. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc. Natl. Acad. Sci. U.S.A., 1994, 91: 614-618.
4. NAPOLI J., BISHOP G.A., MCCAUGHAN G.W. Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. Gastroenterology, 1994, 107: 789-798.
5. NAPOLI J., BISHOP G.A., MCGUINNESS PH., PAINTER D.M., MCCAUGHAN G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology, 1996, 24: 759-765.
6. SCHWEYER S., MIHM S., RADZUN H.J., HARTMANN H., FAYYAZI A. Liver infiltrating T lymphocytes express interferon gamma and inducible nitric oxide synthase in chronic hepatitis C virus infection. Gut, 2000, 46: 255-259.
7. MOSMANN T.R., CHERWINSKI H., BOND M.W., GIEDLIN M.A., COFFMAN R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol., 1986, 136: 2348-2357.
8. MOORE K.W., DE WAAL M., COFFMAN R.L., O'GARRA A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol., 2001, 19: 683-765.
9. LE MOINE O., LOUIS H., SERMON F., GOLDMAN M., DEVIERE J. Interleukin-10 and liver diseases. Acta Gastroenterol. Belg., 1999, 62: 1-8.
10. KNOLLE P.A., UHRIG A., PROTZER U. et al. Interleukin-10 expression is autoregulated at the transcriptional level in human and murine Kupffer cells. Hepatology, 1998, 27: 93-99.
11. KNOLLE P.A., GERKEN G. Local control of the immune response in the liver. Immunol. Rev., 2000, 174: 21-34.
12. KUHN R., LOHLER J., RENNICK D., RAJEWSKY K., MULLER W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 1993, 75: 263-274.
13. RENNICK D., DAVIDSON N., BERG D. Interleukin-10 gene knock-out mice: a model of chronic inflammation. Clin. Immunol. Immunopathol., 1995, 76: S174-S178
14. LE MOINE O., MARCHANT A., DURAND F. et al. Systemic release of interleukin-10 during orthotopic liver transplantation. Hepatology, 1994, 20: 889-892.
15. LE MOINE O., MARCHANT A., DE GROOTE D., AZAR C., GOLDMAN M., DEVIERE J. Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology, 1995, 22: 1436-1439.
16. STREETZ K., LEIFELD L., GRUNDMANN D. et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology, 2000, 119: 446-460.
17. SEKIYAMA K.D., YOSHIBA M., THOMSON A.W. Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and ILreceptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin. Exp. Immunol., 1994, 98: 71-77.
18. YUMOTO E., HIGASHI T., NOUSO K. et al. Serum gamma-interferoninducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J. Gastroenterol. Hepatol., 2002, 17: 285-294.
19. LEIFELD L., CHENG S., RAMAKERS J. et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology, 2002, 36: 1001-1008.
20. LEIST M., GANTNER F., BOHLINGER I., TIEGS G., GERMANN P.G., WENDEL A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am. J. Pathol., 1995, 146: 1220-1234.
21. LEIST M., GANTNER F., JILG S., WENDEL A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J. Immunol., 1995, 154: 1307-1316.
22. LEIST M., GANTNER F., NAUMANN H. et al. Tumor necrosis factorinduced apoptosis during the poisoning of mice with hepatotoxins. Gastroenterology, 1997. 112: 923-934.
23. BRADHAM C.A., PLUMPE J., MANNS M.P., BRENNER D.A., TRAUTWEIN C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am. J. Physiol., 1998, 275: G387-G392
24. LEIFELD L., TRAUTWEIN C., DUMOULIN F.L., MANNS M.P., SAUERBRUCH T., SPENGLER U. Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am. J. Pathol., 1999, 154: 1711-1720.
25. ANDUS T., BAUER J., GEROK W. Effects of cytokines on the liver. Hepatology, 1991, 13: 364-375.
26. LUMSDEN A.B., HENDERSON J.M., KUTNER M.H. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology, 1988, 8: 232-236.
27. ALEXANDER G.J.M., GOKA A.J., SHERON N. The relationship between sepsis, endotoxaemia and cytokines in patients with acute liver failure. In: WILLIAMS R., HUGHES R.D. (eds). Acute liver failure. Proceedings of the eleventh BSG.SK&F International Workshop. London: Smith Kline Beecham, 1991: 22-25.
28. NOLAN J.P. The role of endotoxin in liver injury. Gastroenterology, 1975, 69: 1346-1356.
29. LOUIS H., LE MOINE O., PENY M.O. et al. Hepatoprotective role of interleukin 10 in galactosamine/lipopolysaccharide mouse liver injury. Gastroenterology, 1997, 112: 935-942.
30. LOUIS H., LE MOINE O., PENY M.O. et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology, 1997, 25: 1382-1389.
31. CHOJKIER M., FIERER J. D-Galactosamine hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice. Gastroenterology, 1985, 88: 115-121.
32. HISHINUMA I., NAGAKAWA J., HIROTA K. et al. Involvement of tumor necrosis factor-alpha in development of hepatic injury in galactosaminesensitized mice. Hepatology, 1990, 12: 1187-1191.
33. JAESCHKE H., SMITH C.W. Mechanisms of neutrophil-induced parenchymal cell injury. J. Leukoc. Biol., 1997, 61: 647-653.
34. BOURDI M., MASUBUCHI Y., REILLY T.P. et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology, 2002, 35: 289-298.
35. WINWOOD P.J., ARTHUR M.J. Kupffer cells: their activation and role in animal models of liver injury and human liver disease. Semin. Liver Dis., 1993, 13: 50-59.
36. VAN LAETHEM J.L., ESKINAZI R., LOUIS H., RICKAERT F., ROBBERECHT P., DEVIERE J. Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice. Gut. 1998, 43: 408-413.
37. DEVIERE J., LE MOINE O., VAN LAETHEM J.L. et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology, 2001, 120: 498-505.
38. VOLPES R., VAN DEN OORD J.J., DESMET V.J. Memory T cells represent the predominant lymphocyte subset in acute and chronic liver inflammation. Hepatology, 1991, 13: 826-829.
39. TIEGS G., HENTSCHEL J., WENDEL A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest., 1992, 90: 196-203.
40. MIZUHARA H., O'NEILL E., SEKI N. et al. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J. Exp. Med., 1994, 179: 1529-1537.
41. KUSTERS S., GANTNER F., KUNSTLE G., TIEGS G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology, 1996, 111: 462-471.
42. NICOLETTI F., DI MARCO R., ZACCONE P. et al. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-gamma-dependent mechanism. Hepatology, 2000, 32: 728-733.
43. KANEKO Y., HARADA M., KAWANO T. et al. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J. Exp. Med., 2000, 191: 105-114.
44. MICHALOPOULOS G.K., DEFRANCES M.C. Liver regeneration. Science, 1997, 276: 60-66.
45. LOUIS H., VAN LAETHEM J.L., WU W. et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology, 1998, 28: 1607-1615.
46. RAI R.M., LOFFREDA S., KARP C.L., YANG S.Q., LIN H.Z., DIEHL A.M. Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regenerating rat liver. Hepatology, 1997, 25: 889-895.
47. THURMAN R.G. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am. J. Physiol., 1998, 275: G605-G611.
48. UESUGI T., FROH M., ARTEEL G.E. et al. Role of lipopolysaccharidebinding protein in early alcohol-induced liver injury in mice. J. Immunol., 2002, 168: 2963-2969.
49. UESUGI T., FROH M., ARTEEL G.E., BRADFORD B.U., THURMAN R.G. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology, 2001, 34: 101-108.
50. YIN M., BRADFORD B.U., WHEELER M.D. et al. Reduced early alcohol-induced liver injury in CD14-deficient mice. J. Immunol., 2001, 166: 4737-4742.
51. JARVELAINEN H.A., ORPANA A., PEROLA M., SAVOLAINEN V.T., KARHUNEN P.J., LLNDROS K.O. Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease. Hepatology, 2001, 33: 1148-1153.
52. GROVE J., DALY A.K., BASSENDINE M.F., DAY C.P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology, 1997, 26: 143-146.
53. DEVIERE J., CONTENT J., DENYS C. et al. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology, 1990, 11: 628-634.
54. BIRD G.L., SHERON N., GOKA A.K., ALEXANDER G.J., WILLIAMS R.S. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann. Intern. Med., 1990, 112: 917-920.
55. FELVER M.E., MEZEY E., MC GUIRE M. et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin. Exp. Res., 1990, 14: 255-259.
56. ESKDALE J., GALLAGHER G., VERWEIJ C.L., KEIJSERS V., WESTENDORP R.G., HUIZINGA T.W. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc. Natl. Acad. Sci. U.S.A., 1998, 95: 9465-9470.
57. GROVE J., DALY A.K., BASSENDINE M.F., GILVARRY E., DAY C.P. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease, Gut, 2000, 46: 540-545.
58. LE MOINE O., QUERTINMONT E., GULBIS B., DEVIERE J. Blunted anti-inflammatory response to adenosine in alcoholic cirrhosis. J. Hepatol., 1999, 31: 457-463.
59. NANJI A.A., JOKELAINEN K., RAHEMTULLA A. et al. Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat. Hepatology, 1999, 30: 934-943.
60. DEVIERE J., VAERMAN J.P., CONTENT J. et al. IgA triggers tumor necrosis factor alpha secretion by monocytes: a study in normal subjects and patients with alcoholic cirrhosis. Hepatology, 1991, 13: 670-675.
61. LE MOINE O., DEVIERE J., DEVASTER J.M. et al. Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. J. Hepatol., 1994, 20: 819-824.
62. GONZALEZ-AMARO R., GARCIA-MONZON C., GARCIA-BUEY L. et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J. Exp. Med., 1994, 179: 841-848.
63. GUIDOTTI L.G., ROCHFORD R., CHUNG J., SHAPIRO M., PURCELL R., CHISARI F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 999, 284: 825-829.
64. GUIDOTTI L.G., CHISARI F.V. Cytokine-mediated control of viral infections. Virology, 2000, 273: 221-227.
65. FARCI P., SHIMODA A., COIANA A. et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science, 2000, 288: 339-344.
66. TSAI S.L., LIAW Y.F., CHEN M.H., HUANG C.Y., KUO G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology, 1997, 25: 449-458.
67. KAMAL S.M., RASENACK J.W., BIANCHI L. et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology, 2001, 121: 646656.
68. KAKUMU S., OKUMURA A., ISHIKAWA T., IWATA K., YANO M., YOSHIOKA K. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection. Clin. Exp. Immunol., 1997, 108: 138-143.
69. MAC DONALD A.J., DUFFY M., BRADY M.T. et al. CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J. Infect. Dis., 2002, 185: 720-727.
70. KUZUSHITA N., HAYASHI N., KATAYAMA K. et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand. J. Gastroenterol., 1997, 32: 169-174.
71. EDWARDS-SMITH C.J., JONSSON J.R., PURDIE D.M., BANSAL A., SHORTHOUSE C., POWELL E.E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology, 1999, 30: 526-530.
72. YEE LJ, TANG J., GIBSON A.W., KIMBERLY R., VAN LEEUWEN D.J., KASLOW R.A. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology, 2001, 33: 708-712.
73. MIYAZOE S., HAMASAKI K., NAKATA K. et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am. J. Gastroenterol., 2002, 97: 2086-2092.
74. TAM R.C., PAI B., BARD J. et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol., 1999, 30: 376-382.
75. CRAMP M.E., ROSSOL S., CHOKSHI S., CARUCCI P., WILLIAMS R., NAOUMOV N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology, 2000, 118: 346-355.
76. CARRENO V., ZEUZEM S., HOPF U. et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J. Hepatol., 2000, 32: 317-324.
77. NELSON D.R., LAUWERS G.Y., LAU J.Y., DAVIS G.L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology, 2000, 118: 655-660.
78. MC HUTCHISON J.G., PATEL K. Future therapy of hepatitis C. Hepatology, 2002, 36: S245-S252.
79. Friedman S.L. Cytokines and fibrogenesis. Semin. Liver Dis., 1999, 19: 129-140.
80. MATHURIN P., XIONG S., KHARBANDA K.K. et al. IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 282: G981-G990
81. WANG S.C., OHATA M., SCHRUM L., RIPPE R.A., TSUKAMOTO H. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J. Biol. Chem., 1998, 273: 302-308.
82. THOMPSON K.C., TROWERN A., FOWELL A. et al. Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation In vitro. Hepatology, 1998, 28: 1518-1524.
83. MARRA F. Hepatic stellate cells and the regulation of liver inflammation. J. Hepatol., 1999, 31: 1120-1130.
84. MARRA F., VALENTE A.J., PINZANI M., ABBOUD H.E. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J. Clin. Invest., 1993, 92: 1674-1680.
85. MARRA F., ROMANELLI R.G., GIANNINI C. et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology, 1999, 29: 140-148.
86. THOMPSON K., MALTBY J., FALLOWFIELD J., MC AULAY M., MILLWARD-SADLER H., SHERON N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology, 1998, 28: 1597-1606.
87. DE BLESER PJ., XU G., ROMBOUTS K., ROGIERS V., GEERTS A. Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells. J. Biol. Chem., 1999, 274: 33881-33887.
88. GRANSTEIN R.D., MURPHY G.F., MARGOLIS R.J., BYRNE M.H., AMENTO E.P. Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J. Clin. Invest., 1987, 79: 1254-1258.
89. BARONI G.S., D'AMBROSIO L., CURTO P. et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology, 1996, 23: 1189-1199.
90. WYNN T.A., CHEEVER A.W., JANKOVIC D. et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature, 1995, 376: 594-596.
91. SHI Z., WAKIL A.E., ROCKEY D.C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. U.S.A., 1997, 94: 10663-10668.
92. TSUKAMOTO H. Is interleukin-10 antifibrogenic in chronic liver injury? Hepatology, 1998, 28: 1707-1709.
93. AKDIS C.A., BLESKEN T., AKDIS M., WUTHRICH B., BLASER K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest., 1998, 102: 98-106.
94. GROUX H., BIGLER M., DE VRIES J.E., RONCAROLO M.G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med., 1996, 184: 19-29.
95. GROUX H., O'GARRA A., BIGLER M. et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 1997, 389: 737-742.
96. MALOY K.J., POWRIE F. Regulatory T cells in the control of immune pathology. Nat. Immunol., 2001, 2: 816-822.
97. KNOLLE P.A., UHRIG A., HEGENBARTH S. et al. IL-10 down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules. Clin. Exp. Immunol., 1998, 114: 427-433.
98. LIMMER A., OHL J., KURTS C. et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med., 2000, 6: 1348-1354.
99. WATANABE T., YOSHIDA M., SHIRAI Y., YAMORI M., YAGITA H., ITOH T., CHIBA T., KITA T., WAKATSUKI Y. Administration of an antigen at high dose generates regulatory CD4+ T cells expressing CD95 ligand and secreting IL-4 in the liver. J. Immunol. 2002, 168: 2188-2199.
100. LOUIS H., LE MOINE A., QUERTINMONT E. et al. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology, 2000, 31: 381-390.
101. KALECHMAN Y., GAFTER U., GAL R. et al. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J. Immunol., 2002, 169: 384-392.
102. DING Y., QIN L., KOTENKO S.V., PESTKA S., BROMBERG J.S. A single amino acid determines the immunostimulatory activity of interleukin 10. J. Exp. Med., 2000, 191: 213-224.
103. BERMAN R.M., SUZUKI T., TAHARA H., ROBBINS P.D., NARULA S.K., LOTZE M.T. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J. Immunol., 1996, 157: 231-238.
104. LLORENTE L., ZOU W., LEVY Y. et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med., 1995, 181: 839-844.
105. QIAN S., LI W., LI Y. et al. Systemic administration of cellular interleukin10 can exacerbate cardiac allograft rejection in mice. Transplantation, 1996, 62: 1709-1714.
106. WISSING K.M., MORELON E., LEGENDRE C. et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation, 1997, 64: 999-1006.
107. FEDORAK R.N., GANGL A., ELSON C.O. et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology, 2000, 119: 1473-1482.
108. BLAZAR B.R., TAYLOR P.A., PANOSKALTSIS-MORTARI A. et al. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Transplantation, 1998, 66: 1220-1229.
109. STEIDLER L., HANS W., SCHOTTE L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science, 2000, 289: 1352-1355.
110. VAN MONTFRANS C., HOOIJBERG E., RODRIGUEZ P.M. et al. Generation of regulatory gut-hoing human T lymphocytes using ex vivo interleukin 10 gene transfer. Gastroenterology, 2002, 123: 1877-1888.
111. VAN MONTFRANS C., RODRIGUEZ P.M., PRONK I., TEN KATE F.J., TE V.A., VAN DEVENTER S.J. Prevention of colitis by interleukin 10transduced T lymphocytes in the SCID mice transfer model. Gastroenterology, 2002, 123: 1865-1876.
112. QUATTROCCHI E., DALLMAN M.J., DHILLON A.P., QUAGLIA A., BAGNATO G., FELDMANN M. Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver. J. Immunol., 2001, 166: 5970-5978.